Clinical Trial Update: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on Invikafusp alfa in combination with sacituzumab govitecan in adults with advanced solid tumors, including triple-negative and HR+/HER2-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Invikafusp alfa
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Marengo Therapeutics, Inc. | Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING